{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T19:31:47Z","timestamp":1775071907058,"version":"3.50.1"},"reference-count":19,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["CrossRef Funder ID: 10.13039\/100009945"],"award-info":[{"award-number":["CrossRef Funder ID: 10.13039\/100009945"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Delivery"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1080\/17425247.2024.2311127","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T10:51:35Z","timestamp":1706784695000},"page":"337-346","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Dose accuracy of the follitropin alfa pen injector 2.0, the follitropin alfa:lutropin alfa 2:1 combination pen injector 2.0 and the choriogonadotropin alfa pen injector 1.0 used for fertility treatment"],"prefix":"10.1080","volume":"21","author":[{"given":"Evelyn","family":"Cottell","sequence":"first","affiliation":[{"name":"Merck Healthcare KGaA, Darmstadt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Michalet","sequence":"additional","affiliation":[{"name":"Ares Trading S.A. Eysins (An affiliate of Merck KGaA), Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Lispi","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA, Darmstadt, Germany"},{"name":"School of Clinical and Experimental Medicine, Unit of Endocrinology, University of Modena and Reggio Emilia, Modena, MO, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiago Dantas","family":"Araujo","sequence":"additional","affiliation":[{"name":"Ares Trading S.A. Eysins (An affiliate of Merck KGaA), Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Gleixner","sequence":"additional","affiliation":[{"name":"Ares Trading S.A. Eysins (An affiliate of Merck KGaA), Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Longobardi","sequence":"additional","affiliation":[{"name":"Global Clinical Development, Merck Serono S.p.A, Rome, Italy, an affiliate of Merck KGaA, Darmstadt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"D\u2019Hooghe","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA, Darmstadt, Germany"},{"name":"Department of Development and Regeneration, Laboratory of Endometrium, Endometriosis &amp; Reproductive Medicine, KU Leuven, Leuven, Belgium"},{"name":"Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University Medical School, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00429"},{"key":"e_1_3_7_4_1","unstructured":"FDA. Highlights of prescribing information for gonal-f RFF redi-ject 2013 [cited 2022 Jan 18]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021684s036lbl.pdf"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2017.1237940"},{"key":"e_1_3_7_6_1","unstructured":"EMA. GONAL-f: summary of product characteristics. The Netherlands: European Medicines Agency. 2023 [cited 2023 Oct 11]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/gonal-f-epar-product-information_en.pdf"},{"key":"e_1_3_7_7_1","unstructured":"EMA. Ovitrelle: summary of product characteristics. The Netherlands: European Medicines Agency; 2021 [cited 2022 Jan 18]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ovitrelle-epar-product-information_en.pdf"},{"key":"e_1_3_7_8_1","unstructured":"EMA. Pergoveris: summary of product characteristics. The Netherlands: European Medicines Agency; 2021 [cited 2022 Jan 18]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pergoveris-epar-product-information_en.pdf"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S21421"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.10.006"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2019.1651290"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2021-10-3"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-021-00882-2"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2017.1289174"},{"key":"e_1_3_7_15_1","unstructured":"ISO. ISO 11608-1: needle-based injection systems for medical use \u2014 requirements and test methods \u2014 part 1: needle-based injection systems 2014 [cited 2022 Jan 18]. Available from: www.iso.org\/standard\/65021.html"},{"key":"e_1_3_7_16_1","unstructured":"FDA. Technical considerations for pen jet and related injectors intended for use with drugs and biological products. 2020 [cited 2022 Jan 18]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/technical-considerations-pen-jet-and-related-injectors-intended-use-drugs-and-biological-products"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2015.1033395"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2011.581658"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2018.1450386"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2012.698607"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2021.1863944"}],"container-title":["Expert Opinion on Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425247.2024.2311127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T13:38:41Z","timestamp":1727185121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425247.2024.2311127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1080\/17425247.2024.2311127"],"URL":"https:\/\/doi.org\/10.1080\/17425247.2024.2311127","relation":{},"ISSN":["1742-5247","1744-7593"],"issn-type":[{"value":"1742-5247","type":"print"},{"value":"1744-7593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-06-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}